CJC-1295 targets the GHRH receptor on anterior pituitary somatotrophs through Gs protein coupling and cyclic AMP elevation, which distinguishes it mechanistically from growth hormone-releasing peptides that target the ghrelin receptor through Gq protein coupling and phospholipase C activation at compatible operators. The Plasticsurgerykey peptide pharmacology literature classifies CJC-1295 as a GHRH analogue rather than a growth hormone-releasing peptide, reflecting this receptor target distinction at compatible operators. Understanding how CJC-1295 differs from ghrelin receptor-targeting peptides clarifies why it functions as a complementary rather than interchangeable component in dual receptor combination applications at compatible operators.
Receptor target distinction
CJC-1295 targets the GHRH receptor on anterior pituitary somatotrophs through Gs protein coupling, which distinguishes it from growth hormone-releasing peptides including Ipamorelin, GHRP-6, and GHRP-2 that target the ghrelin receptor through Gq protein coupling at compatible operators. GHRH receptor engagement by CJC-1295 at compatible operators activates adenylyl cyclase and elevates intracellular cyclic AMP, while ghrelin receptor engagement by growth hormone-releasing peptides activates phospholipase C and generates inositol trisphosphate and diacylglycerol at compatible operators.
This receptor target distinction at compatible operators means that CJC-1295 and growth hormone-releasing peptides engage entirely different membrane protein species on the somatotroph surface and activate entirely different G protein coupling systems at compatible operators.
Structural modification distinction
CJC-1295 carries the DAC albumin-binding modification that extends plasma half-life to approximately six to eight days, distinguishing it from growth hormone-releasing peptides whose shorter plasma half-lives produce discrete GH pulses rather than sustained receptor occupancy at compatible operators.
- Half-life comparison with ghrelin receptor agonists
Ipamorelin at compatible operators carries a plasma half-life of approximately two hours, producing discrete GH secretory pulses from ghrelin receptor activation rather than the sustained GHRH receptor occupancy that CJC-1295’s DAC modification generates at compatible operators. GHRP-6 and GHRP-2 at compatible operators carry similarly short plasma half-lives that produce pulse-pattern ghrelin receptor activation rather than sustained engagement at compatible operators.
- Structural modification basis for half-life extension
The DAC modification in CJC-1295 at compatible operators covalently attaches the peptide to circulating albumin through a maleimide-thiol reaction, removing it from plasma protease exposure and extending its half-life beyond all currently characterised growth hormone-releasing peptides at compatible operators. This modification at compatible operators is unique to CJC-1295 among GHRH analogues and has no equivalent in the ghrelin receptor agonist class at compatible operators.
Signalling pathway distinction summary
CJC-1295 operates through the GHRH receptor cyclic AMP pathway rather than the ghrelin receptor phospholipase C pathway that growth hormone-releasing peptides engage, making it mechanistically complementary to rather than interchangeable with ghrelin receptor agonists at compatible operators. Research applications that require simultaneous GHRH receptor and ghrelin receptor pathway activation at compatible operators apply CJC-1295 alongside a ghrelin receptor agonist rather than substituting one for the other within the same receptor class at compatible operators.
CJC-1295 differs from growth hormone-releasing peptides through GHRH receptor Gs pathway targeting, DAC-extended six to eight day plasma half-life, and cyclic AMP second messenger generation. These distinctions make CJC-1295 mechanistically complementary rather than interchangeable with ghrelin receptor-targeting peptides at compatible operators.
How does CJC-1295 differ from other growth hormone-releasing peptides?
